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LETTER TO THE EDITOR
Azelnidipine, but not amlodipine, 
reduces urinary albumin excretion and carotid 
atherosclerosis in subjects with type 2 diabetes: 
blood pressure control with olmesartan 
and azelnidipine in Type 2 diabetes (BOAT2 
study)
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Masashi Shimoda1, Shinji Kamei1, Michihiro Matsuki1, Tomoatsu Mune1 and Kohei Kaku3
Abstract 
To evaluate the efficacy of azelnidipine and amlodipine on diabetic nephropathy and atherosclerosis, we designed 
a prospective and randomized controlled clinical study in type 2 diabetic patients with stable glycemic control with 
fixed dose of anti-diabetic medication. Although there was no difference in blood pressure between both groups, 
urinary albumin excretion and maximum carotid intima-media thickness were reduced in azelnidipine group, but not 
in amlodipine group. In addition, inflammatory cytokine levels were decreased only in azelnidipine group which pos-
sibly explains such beneficial effects of azelnidipine on urinary albumin excretion and carotid atherosclerosis.
© 2015 Tawaramoto et al.  This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dear Editor,
It is well known that both type 2 diabetes and hyperten-
sion lead to the onset of cerebrovascular and cardiovas-
cular events via the augmentation of inflammation and 
the progression of atherosclerosis. Therefore, physicians 
have to choose the most appropriate medication for the 
prevention of such complications. Diabetic nephropa-
thy is also one of the life-threatening major complica-
tions and its progression is accelerated in the presence 
of hypertension [1, 2]. Angiotensin receptor II blockers 
(ARBs) are recommended as a first medication to treat 
hypertension in patients with type 2 diabetes, and cal-
cium channel blockers (CCBs) are often selected as a sec-
ond anti-hypertensive medication. Among many CCBs, 
azelnidipine is known to possess unique effect such as 
higher anti-inflammatory effect. Therefore, we hypoth-
esized that azelnidipine is more effective to delay the pro-
gression of atherosclerosis and/or diabetic nephropathy, 
and designed a prospective, two-arm, randomized con-
trolled clinical study with azelnidipine and amlodipine. 
This study was conducted with outpatients in division 
of Diabetes, Endocrinology and Metabolism in Kawa-
saki Medical School. The study protocol was approved by 
Institutional Review Board of Kawasaki Medical School, 
and the study was conducted in accordance with the 
Declaration of Helsinki.
We enrolled a total of 38 subjects with type 2 diabe-
tes whose blood pressure was not sufficiently controlled 
by treatment with 20  mg/day of olmesartan for over 
2  months. Insufficient control was defined as follows: 
systolic blood pressure >130  mmHg and/or diastolic 
blood pressure >80 mmHg according to the guideline by 
Japanese Society of Hypertension. Patients who signed 
an informed consent prior to this trial were randomly 
divided in azelinidipine (16  mg/day) and amlodipine 
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group (5  mg/day). We evaluated the effects of azelnidi-
pine and amlodipine after 32  weeks. Patients who met 
inclusion criteria were as follows: patients with type 2 
diabetes and without well-controlled blood pressure by 
treatment with olmesartan; 40 < age < 75 years old; hemo-
globin A1c (NGSP) is below 9.4 %. The following patients 
were excluded: with suspiciously secondary hyperten-
sion or non-diabetic kidney disease; with congenital dys-
lipidemia or extremely high LDL-cholesterol (>200  mg/
dl); with advanced hepatic disease (AST  >  75  IU/ml) 
or advanced renal failure (Crn  >  2.0  mg/dl for male, 
Crn > 1.5 mg/dl for female); in pregnancy; with current 
history of any malignant neoplasm; with using steroids, 
any hormonal medications, any diuretics, immune-
suppressing medications and/or potassium drug; with 
past history of stroke or myocardial infarction occurring 
within past 6  months from the start of the trial. There 
was no dropout during the follow-up period.
Carotid IMT was measured using Aplio ultrasonog-
raphy (Toshiba), and images of carotid artery were 
scanned by computer and analyzed using IntimaScope 
software (MEDIA CROSS). Plasma MCP-1 (R&D sys-
tems), TNF-α (R&D systems), HMW adiponectin (R&D 
systems), leptin (R&D systems), soluble vascular cell 
adhesion molecule-1 (VCAM-1) (R&D systems) and 
soluble intercellular adhesion molecule-1 (ICAM-1) 
Table 1 Baseline clinical data in azelnidipine and amlodipine groups
ns not significant (azelnidipine vs amlodipine at baseline)
p < 0.05 azelnidipine vs amlodipine at baseline
Azelnidipine (n = 19) Amlodipine (n = 19) P
Before After Before After
Gender (male/female) 9/10 ND 8/11 ND
Age (years) 59 ± 2 ND 63 ± 2 ND n.s.
BMI (kg/m2) 25.8 ± 1.0 ND 27.1 ± 1.0 ND n.s.
Durations of DM (years) 9.2 ± 2.3 ND 11.3 ± 2.2 ND n.s.
Systolic BP (mmHg) 149 ± 2.4 128 ± 2.9 148 ± 2.9 129 ± 3.3 n.s.
Diastolic BP (mmHg) 80 ± 2.4 68 ± 2.3 84 ± 2.3 72 ± 2.1 n.s.
Heart rate (beats/min) 75 ± 2.8 71 ± 2.5 68 ± 2.3 69 ± 3.5 <0.05
HbA1c (NGSP) (%) 6.9 ± 0.2 6.9 ± 0.2 7.2 ± 0.2 7.3 ± 0.3 n.s.
Fasting plasma glucose (mg/dl) 126 ± 6.4 128 ± 12.3 120 ± 4.6 130 ± 7.5 n.s.
Total cholesterol (mg/dl) 200 ± 6.3 196 ± 7.4 207 ± 6.1 196 ± 5.5 n.s.
HDL cholesterol (mg/dl) 57 ± 3.0 55 ± 3.3 55 ± 3.1 55 ± 2.2 n.s.
LDL cholesterol (mg/dl) 117 ± 6.8 113 ± 6.5 122 ± 4.9 113 ± 5.1 n.s.
Triglyceride (mg/dl) 129 ± 13.4 136 ± 18.0 144 ± 11.4 142 ± 13.4 n.s.
Creatinine (mg/dl) 0.69 ± 0.06 0.76 ± 0.04 0.70 ± 0.04 0.69 ± 0.04 n.s.
BUN (mg/dL) 17.3 ± 1.1 17.1 ± 0.9 17.2 ± 0.8 17.9 ± 0.7 n.s.
eGFR (ml/min/1.73 m2) 75.2 ± 3.6 73.2 ± 3.6 76.9 ± 3.2 78.2 ± 3.3 n.s.
Urinary albumin excretion (mg/g.Cr) 274 ± 202 121 ± 69 136 ± 70 202 ± 114 n.s.
Uric acid (mg/dl) 5.7 ± 0.4 5.7 ± 0.3 5.5 ± 0.3 5.5 ± 0.4 n.s.
Na (mEq/l) 141 ± 0.4 141 ± 0.5 141 ± 0.4 140 ± 0.5 n.s.
K (mEq/l) 4.4 ± 0.1 4.5 ± 0.1 4.2 ± 0.1 4.2 ± 0.1 n.s.
Cl (mEq/l) 105 ± 0.4 104 ± 0.5 105 ± 0.5 104 ± 0.4 n.s.
average IMT (mm) 0.817 ± 0.054 0.759 ± 0.034 0.873 ± 0.063 0.814 ± 0.080 n.s.
Max IMT (mm) 1.102 ± 0.101 0.908 ± 0.004 1.203 ± 0.113 1.124 ± 0.143 n.s.
Other medications
 Sulfonylurea (%) 7 (36.8) 7 (36.8)
 Metformin (%) 6 (31.6) 7 (36.8)
 Pioglitazone (%) 9 (47.4) 8 (42.1)
 α-glucosidase inhibitors (%) 4 (21.1) 2 (10.5)
 Insulin (%) 1 (5.3) 2 (10.5)
 Fibrate (%) 2 (10.5) 3 (15.8)
 Statins (%) 8 (42.1) 7 (36.8)
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(RayBiotech) were measured using enzyme-linked 
immunosorbent assay kits. All values were expressed 
as mean  ±  s.e.m. We used the Mann–Whitney U test 
for unpaired data and the Wilcoxon signed-rank test for 
paired data.
There was no difference between the two groups in any 
clinical background including age, BMI, duration of dia-
betes, blood pressure and biochemical laboratory data 
except for heart rate (Table 1). Heart rate was higher in 
azelnidipine group. In addition, there was no difference 
between the two groups about treatment of any anti-dia-
betic or anti-dyslipidemic medication (Table 1). In both 
groups, systolic and diastolic blood pressure were signifi-
cantly reduced during the trial (p < 0.05), but the efficacy 
of lowering blood pressure was similar (Fig.  1a). Heart 
rate was significantly decreased only in azelnidipine 
group (p < 0.05), although we cannot exclude the possi-
bility that the difference of the effects on heart rate was 
influenced by the difference at baseline and there was not 
statistically significant difference in heart rate between 
the two groups at follow-up point.
At baseline, there was no difference in glucose and lipid 
metabolism between the two groups (Table  1). HbA1c, 
fasting plasma glucose and fasting plasma insulin levels 
were not altered during the treatment with azelnidipine 
or amlodipine (Table  1). Plasma triglyceride, LDL-cho-
lesterol and HDL-cholesterol levels were not also altered 
(Table 1). At baseline, there was no difference in urinary 
albumin excretion between the two groups. Urinary 
albumin excretion was significantly reduced after azel-
nidipine treatment (p  <  0.05), but not after amlodipine 
treatment (Fig.  1b, left). Urinary albumin excretion in 
azelnidipine group was significantly lowered compared to 
amlodipine group (p < 0.05) (Fig. 1b, right), although we 
cannot exclude the possibility that the difference of the 
effects on urinary albumin excretion was influenced by 
the difference of mean value in urinary albumin excretion 
at baseline. Max IMT was significantly decreased only in 
azelnidipine group at 32 weeks (p < 0.05), although aver-
age IMT was not altered in both groups (Fig. 1c).
Inflammation is regarded as a key factor of athero-
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Fig. 1 a Blood pressure and pulse rate in amlodipine and azelnidipine groups. Urinary albumin excretion (b) and carotid intima-media thickness 
(IMT) (c) in amlodipine and azelnidipine groups. Inflammatory factors (d), adipocytokines (e) and soluble adhesion factors (f), in amlodipine and 
azelnidipine groups. Closed square and bar, amlodipine (n = 19); open triangle and bar, azelnidipine (n = 19). *p < 0.05, #p = 0.055
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vascular endothelial cells secrete various inflammatory 
cytokines including MCP-1 and TNF-α. In addition, it 
was reported that azelnidipine reduced inflammation 
[3, 4]. It is also known that various adipocytokines are 
key molecules for the improvement of urinary albumin 
excretion [4] and that cohesion of leukocytes on vascular 
endothelial cell wall is accelerated by VCAM-1 or ICAM-
1. Therefore, to explore the mechanism how azelnidipine 
decreased urinary albumin excretion and carotid ath-
erosclerosis, we evaluated plasma levels of inflammatory 
cytokines, adipocytokines and soluble adhesion factors. 
As shown in Fig.  1d, plasma MCP-1 levels were signifi-
cantly reduced only in azelnidipine group (p < 0.05), and 
TNF-α levels were also reduced only in azelnidipine 
group (p = 0.055). There was no difference between the 
two groups in the effects on HMW adiponectin and lep-
tin levels (Fig. 1e) and soluble VCAM-1 and ICAM-1 lev-
els (Fig. 1f ). These data suggest that azelnidipine affects 
inflammatory axis rather than adhesion molecules or adi-
pocytokines. We assume that such effects of azelnidipine 
leads to the reduction of urinary albumin excretion and 
carotid atherosclerosis.
It is noted here that there is a limitation in this study. 
First, we compared the effects of azelnidipine and 
amlodipine, and there was no placebo group in this study. 
Second, since sample size was small and we did not per-
form sample size/power calculation in this study, fur-
ther study with larger sample size would be necessary to 
strengthen the idea obtained in this study. Finally, since 
we failed to evaluate smoking habit which is a risk factor 
to develop atherosclerosis, we cannot exclude the possi-
bility that the difference of the effects between the two 
drugs was influenced by the difference of smoking habit.
In summary, both azelnidipine (16  mg/day) and 
amlodipine (5  mg/day) have similar ability to decrease 
blood pressure in hypertensive patients complicated with 
type 2 diabetes. However, azelnidipine delayed the pro-
gression of urinary albumin excretion and carotid athero-
sclerosis, which was not observed with amlodipine. We 
assume that the reduction of inflammation by azelnidi-
pine explains, at least in part, its beneficial effects on uri-
nary albumin excretion and carotid atherosclerosis.
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